Table 2:

Demographic and cognitive clinical variables of the subjects included in this studya

Cognitive ExaminationFirst Follow-Up (n = 65)Second Follow-Up (n = 32)
Age (mean) (range) (yr)36.5 (SD, 10.1) (21–62)45.9 (SD, 10.5) (29–61)
Sex (M/F)26:3913:19
DD (mean) (yr)15.0 (SD, 7.1)18.6 (SD, 7.7)
SDMT z score (mean)–1.3 (SD, 1.2)–1.1 (SD, 1.1)
BVMT z score (mean)–0.9 (SD, 1.5)–0.6 (SD, 1.4)
CVLT z score (mean)–0.6 (SD, 1.4)–0.4 (SD, 1.5)
BICAMS z score (mean)–0.9 (SD, 1.1)–0.7 (SD, 1.0)
FU time from baseline (mean) (yr)4.6 (SD, 1.0)7.5 (SD, 0.7)
ΔBICAMS (mean)NA–0.3 (SD, 0.8)
Cognitive impairment (impaired/preserved)40/25NA
Cognitive progressionNA5/32 (15.6%)
  • Note:—FU indicates follow-up.

  • a Cognitive impairment at the first time point was defined if a subject showed at least one of the z score values of equal or less than –1.5. Cognitive worsening at second time point was defined in case of ΔBICAMS equal or less than –0.5.